# Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

> **NCT06708858** · PHASE2 · RECRUITING · sponsor: **Dai, Guanghai** · enrollment: 35 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Durvalumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06708858
- **Lead sponsor:** Dai, Guanghai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2025-12
- **Final completion:** 2027-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708858, "Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06708858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*